Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study

Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study

IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A16356-A16356
Hauptverfasser: Kuwabara, Masanari, Kaneko, Tetsuji, Komatsu, Ikki, Komiyama, Nobuyuki, Ohashi, Yasuo, Nagai, Ryozo, Iimuro, Satoshi
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A16356
container_issue Suppl_1 Suppl 1
container_start_page A16356
container_title Circulation (New York, N.Y.)
container_volume 140
creator Kuwabara, Masanari
Kaneko, Tetsuji
Komatsu, Ikki
Komiyama, Nobuyuki
Ohashi, Yasuo
Nagai, Ryozo
Iimuro, Satoshi
description IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared with low-dose statin, which affected the main results.MethodsThis study retrospectively analyzed the REAL-CAD database of 13,054 patients with stable CAD. We compared the levels of serum uric acid change between high-dose statin and low-dose statin 6 months later from study onset. Moreover, we checked if hyperuricemia, defined as >7.0 mg/dL in men and ≥6.0 mg/dL in women, causes cardiovascular events. We calculated hazard ratio (HR) of hyperuricemia for cardiovascular events after multivariable adjustments with age, sex, body mass index, smoking habits, diabetes, hypertension, chronic kidney disease, LDL-cholesterol, high-sense CRP (hs-CRP), white blood cell (WBC), and hyperuricemia.ResultsThe full analysis population consisted of 12,413 Japanese patients (68.1±8.3 years old, 82.6% men). Of those, 9,673 patients at the baseline and 9,698 patients at 6 months later from study onset had checked their serum uric acid levels. High-dose group showed significantly larger serum uric acid change over 6 months than low-dose group (-0.1505 mg/dL versus -0.0046 mg/dL, P
doi_str_mv 10.1161/circ.140.suppl_1.16356
format Article
fullrecord <record><control><sourceid>wolterskluwer</sourceid><recordid>TN_cdi_wolterskluwer_health_00003017-201911191-03693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00003017-201911191-03693</sourcerecordid><originalsourceid>FETCH-wolterskluwer_health_00003017-201911191-036933</originalsourceid><addsrcrecordid>eNqdjttKxDAQhoMoWA-vIPMCqZmmB6pXZQ-s4NWu9yXbZtm4sS2ZxKVvb5R9Ai--GX74v2EYe0KRIpb43BnXpZiLlMI02RZTLGVRXrEEiyzneSHra5YIIWpeySy7ZXdEnzGWsioSNjd78k51Hv6sF9jMk3bBmU5_GQWGQA3wNvR60nEMHraGTrCOwujgEFko15vxW1EXrHKwNKQV6VdoYBf2vBmUnSle-a1uV807XzRL2PnQzw_s5qAs6cfLvmf5evWx2PDzaL12dLLhrF171Mr6YxsfFlJgxTOBNWKEC1nWUv5T-wGeIVyS</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study</title><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Kuwabara, Masanari ; Kaneko, Tetsuji ; Komatsu, Ikki ; Komiyama, Nobuyuki ; Ohashi, Yasuo ; Nagai, Ryozo ; Iimuro, Satoshi</creator><creatorcontrib>Kuwabara, Masanari ; Kaneko, Tetsuji ; Komatsu, Ikki ; Komiyama, Nobuyuki ; Ohashi, Yasuo ; Nagai, Ryozo ; Iimuro, Satoshi</creatorcontrib><description>IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared with low-dose statin, which affected the main results.MethodsThis study retrospectively analyzed the REAL-CAD database of 13,054 patients with stable CAD. We compared the levels of serum uric acid change between high-dose statin and low-dose statin 6 months later from study onset. Moreover, we checked if hyperuricemia, defined as &gt;7.0 mg/dL in men and ≥6.0 mg/dL in women, causes cardiovascular events. We calculated hazard ratio (HR) of hyperuricemia for cardiovascular events after multivariable adjustments with age, sex, body mass index, smoking habits, diabetes, hypertension, chronic kidney disease, LDL-cholesterol, high-sense CRP (hs-CRP), white blood cell (WBC), and hyperuricemia.ResultsThe full analysis population consisted of 12,413 Japanese patients (68.1±8.3 years old, 82.6% men). Of those, 9,673 patients at the baseline and 9,698 patients at 6 months later from study onset had checked their serum uric acid levels. High-dose group showed significantly larger serum uric acid change over 6 months than low-dose group (-0.1505 mg/dL versus -0.0046 mg/dL, P&lt;0.001). In non-adjusted (crude) analysis, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.49; 95% CI, 1.22-1.82). After multivariable adjustments, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.30; 95% CI, 1.04-1.62), as well as aging, male, hypertension, diabetes, chronic kidney disease, higher hs-CPR, and higher WBC. The landmark analysis at 6 month later from study onset showed the similar results.ConclusionsHigh-dose pitavastatin significantly reduced serum uric acid levels than low-dose pitavastatin. Hyperuricemia is an independent risk factor for cardiovascular events in patients with stable CAD. The serum uric acid lowering effects by pitavastatin could affect the main results of the REAL-CAD study.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/circ.140.suppl_1.16356</identifier><language>eng</language><publisher>by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><ispartof>Circulation (New York, N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A16356-A16356</ispartof><rights>2019 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Kuwabara, Masanari</creatorcontrib><creatorcontrib>Kaneko, Tetsuji</creatorcontrib><creatorcontrib>Komatsu, Ikki</creatorcontrib><creatorcontrib>Komiyama, Nobuyuki</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Nagai, Ryozo</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><title>Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study</title><title>Circulation (New York, N.Y.)</title><description>IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared with low-dose statin, which affected the main results.MethodsThis study retrospectively analyzed the REAL-CAD database of 13,054 patients with stable CAD. We compared the levels of serum uric acid change between high-dose statin and low-dose statin 6 months later from study onset. Moreover, we checked if hyperuricemia, defined as &gt;7.0 mg/dL in men and ≥6.0 mg/dL in women, causes cardiovascular events. We calculated hazard ratio (HR) of hyperuricemia for cardiovascular events after multivariable adjustments with age, sex, body mass index, smoking habits, diabetes, hypertension, chronic kidney disease, LDL-cholesterol, high-sense CRP (hs-CRP), white blood cell (WBC), and hyperuricemia.ResultsThe full analysis population consisted of 12,413 Japanese patients (68.1±8.3 years old, 82.6% men). Of those, 9,673 patients at the baseline and 9,698 patients at 6 months later from study onset had checked their serum uric acid levels. High-dose group showed significantly larger serum uric acid change over 6 months than low-dose group (-0.1505 mg/dL versus -0.0046 mg/dL, P&lt;0.001). In non-adjusted (crude) analysis, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.49; 95% CI, 1.22-1.82). After multivariable adjustments, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.30; 95% CI, 1.04-1.62), as well as aging, male, hypertension, diabetes, chronic kidney disease, higher hs-CPR, and higher WBC. The landmark analysis at 6 month later from study onset showed the similar results.ConclusionsHigh-dose pitavastatin significantly reduced serum uric acid levels than low-dose pitavastatin. Hyperuricemia is an independent risk factor for cardiovascular events in patients with stable CAD. The serum uric acid lowering effects by pitavastatin could affect the main results of the REAL-CAD study.</description><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqdjttKxDAQhoMoWA-vIPMCqZmmB6pXZQ-s4NWu9yXbZtm4sS2ZxKVvb5R9Ai--GX74v2EYe0KRIpb43BnXpZiLlMI02RZTLGVRXrEEiyzneSHra5YIIWpeySy7ZXdEnzGWsioSNjd78k51Hv6sF9jMk3bBmU5_GQWGQA3wNvR60nEMHraGTrCOwujgEFko15vxW1EXrHKwNKQV6VdoYBf2vBmUnSle-a1uV807XzRL2PnQzw_s5qAs6cfLvmf5evWx2PDzaL12dLLhrF171Mr6YxsfFlJgxTOBNWKEC1nWUv5T-wGeIVyS</recordid><startdate>20191119</startdate><enddate>20191119</enddate><creator>Kuwabara, Masanari</creator><creator>Kaneko, Tetsuji</creator><creator>Komatsu, Ikki</creator><creator>Komiyama, Nobuyuki</creator><creator>Ohashi, Yasuo</creator><creator>Nagai, Ryozo</creator><creator>Iimuro, Satoshi</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope/></search><sort><creationdate>20191119</creationdate><title>Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study</title><author>Kuwabara, Masanari ; Kaneko, Tetsuji ; Komatsu, Ikki ; Komiyama, Nobuyuki ; Ohashi, Yasuo ; Nagai, Ryozo ; Iimuro, Satoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-wolterskluwer_health_00003017-201911191-036933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Kuwabara, Masanari</creatorcontrib><creatorcontrib>Kaneko, Tetsuji</creatorcontrib><creatorcontrib>Komatsu, Ikki</creatorcontrib><creatorcontrib>Komiyama, Nobuyuki</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Nagai, Ryozo</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuwabara, Masanari</au><au>Kaneko, Tetsuji</au><au>Komatsu, Ikki</au><au>Komiyama, Nobuyuki</au><au>Ohashi, Yasuo</au><au>Nagai, Ryozo</au><au>Iimuro, Satoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>2019-11-19</date><risdate>2019</risdate><volume>140</volume><issue>Suppl_1 Suppl 1</issue><spage>A16356</spage><epage>A16356</epage><pages>A16356-A16356</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>IntroductionREAL-CAD study showed that high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in patients with stable coronary artery disease (CAD).HypothesisWe hypothesized that high-dose statin reduced serum uric acid levels compared with low-dose statin, which affected the main results.MethodsThis study retrospectively analyzed the REAL-CAD database of 13,054 patients with stable CAD. We compared the levels of serum uric acid change between high-dose statin and low-dose statin 6 months later from study onset. Moreover, we checked if hyperuricemia, defined as &gt;7.0 mg/dL in men and ≥6.0 mg/dL in women, causes cardiovascular events. We calculated hazard ratio (HR) of hyperuricemia for cardiovascular events after multivariable adjustments with age, sex, body mass index, smoking habits, diabetes, hypertension, chronic kidney disease, LDL-cholesterol, high-sense CRP (hs-CRP), white blood cell (WBC), and hyperuricemia.ResultsThe full analysis population consisted of 12,413 Japanese patients (68.1±8.3 years old, 82.6% men). Of those, 9,673 patients at the baseline and 9,698 patients at 6 months later from study onset had checked their serum uric acid levels. High-dose group showed significantly larger serum uric acid change over 6 months than low-dose group (-0.1505 mg/dL versus -0.0046 mg/dL, P&lt;0.001). In non-adjusted (crude) analysis, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.49; 95% CI, 1.22-1.82). After multivariable adjustments, hyperuricemia at the baseline is an independent risk factor for cardiovascular event (HR1.30; 95% CI, 1.04-1.62), as well as aging, male, hypertension, diabetes, chronic kidney disease, higher hs-CPR, and higher WBC. The landmark analysis at 6 month later from study onset showed the similar results.ConclusionsHigh-dose pitavastatin significantly reduced serum uric acid levels than low-dose pitavastatin. Hyperuricemia is an independent risk factor for cardiovascular events in patients with stable CAD. The serum uric acid lowering effects by pitavastatin could affect the main results of the REAL-CAD study.</abstract><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub><doi>10.1161/circ.140.suppl_1.16356</doi></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A16356-A16356
issn 0009-7322
1524-4539
language eng
recordid cdi_wolterskluwer_health_00003017-201911191-03693
source American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
title Abstract 16356: Hyperuricemia is an Independent Risk Factor for Cardiovascular Disease; A Sub-Analysis for REAL-CAD Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%2016356:%20Hyperuricemia%20is%20an%20Independent%20Risk%20Factor%20for%20Cardiovascular%20Disease;%20A%20Sub-Analysis%20for%20REAL-CAD%20Study&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Kuwabara,%20Masanari&rft.date=2019-11-19&rft.volume=140&rft.issue=Suppl_1%20Suppl%201&rft.spage=A16356&rft.epage=A16356&rft.pages=A16356-A16356&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/circ.140.suppl_1.16356&rft_dat=%3Cwolterskluwer%3E00003017-201911191-03693%3C/wolterskluwer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true